The cost of waiting: what licensing a biotech asset early really saves you

The cost of waiting: what licensing a biotech asset early really saves you Joseph Ferner Add Labiotech as your Google Preferred Source 7 minutesmins August 21, 2026 7 minutesmins Share WhatsApp Twitter Linkedin Email Phot credit: Ousa Chea (Unsplash) Add Labiotech as your Google Preferred Source Newsletter Signup - Under Article / In Page"*" indicates required fieldsNameThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* In recent years, biopharma has paid significantly different prices for the same underlying technology. In March 2025, AstraZeneca agreed to pay EsoBiotec, an in vivo CAR-T platform with early single-patient data, $425 million upfront and up to $575 million more in milestones. In August 2025, Gilead’s Kite paid $350 million for Interius BioTherapeutics, another in vivo CAR-T platform, also lentiviral, also in an ongoing Phase 1 trial, entirely in cash with no further payments attached. In April 2026, Eli Lilly agreed to pay Kelonia Therapeutics, a third lentiviral in vivo CAR-T platform, also in Phase 1, $3.25 billion upfront, rising to as much as $7 billion in milestones.All three deals were struck at the same clinical stage and none of the companies was later than the others. What separated two deals guaranteed under $500 million from one guaranteeing well over $3 billion was most likely the strength of the data on the table: Kelonia’s lead candidate had shown a 100% early measurable residual disease-negative response, presented at ASH’s 2025 plenary session, against a single-patient signal for EsoBiotec and an unremarked-on ongoing trial for Interius. This is worth naming plainly, because it changes what “being late” actually means in this market. It doesn’t mean showing up in 2026 instead of 2025. It means waiting for proof that has already convinced everyone else, at which point the price reflects how convinced everyone else already is.Table of contentsWhere the pipeline is genuinely earlyEvery one of those deals happened downstream of the point where a therapy or technology is genuinely difficult to price. None of EsoBiotec, Interius, or Kelonia was an academic discovery when their eventual acquirers first became aware of them. All three were already funded, incorporated biotechs running clinical trials.The earlier stage, the one no public deal tracker prices, is the academic and institutional tech-transfer pipeline: the assets sitting inside university labs and research centers before anyone has built a company around them. Data from Inpart’s partnering network, Connect shows the rate of new CAR-T opportunities being published has more than tripled over the past three years. The total pool of published CAR-T opportunities on the platform now stands at 190, and the pace so far in 2026 is on track to exceed last year’s total. Industry engagement has kept pace. Partnering conversations started per CAR-T opportunity rose by 57% over the last year. Engagement density is intensifying as the pipeline continues to grow. This still only accounts for around 1 partnering conversation started in every 5 CAR-T opportunities over the last six months, up from roughly 1 in 10 in the preceding six months. This suggests that the majority of a steadily growing, increasingly competitive pipeline is still flying under the radar. All this in a modality where the eventual price of entry, once that pipeline resolves into funded companies with trial data, is already running into the billions.What building it yourself actually costsThe obvious response to a $7 billion price tag is to ask what the alternative costs. Academic licensing deals, one of the most common mechanisms through which early-stage opportunities like those on Inpart Connect are absorbed by industry, are considerably cheaper to enter than commercial biotech licenses. A peer-reviewed analysis of 239 academic-to-industry biotechnology licenses, compared against 916 commercial licenses over the same period, found academic deals carried a median precommercial payment of $1.1 million, against $25.4 million for commercial licenses, roughly a twentyfold gap. Academic deals also carried lower royalty rates, a median of 3% against 8% for commercial licenses.Suggested Articles Unlocking the power of mRNA technology Can European Biotech Companies Afford Not to Work with China? How will European Commission proposals on data exclusivity and the bolar exemption affect pharma companies? How Culture Impacts Biotech Investment That upfront cost does not include what it takes to develop the asset yourself once licensed. One of the most rigorous published estimates of that cost comes from a 2023 peer-reviewed analysis in Pharmaceutical Medicine, authored by two EY analysts using SEC-reported spend across 11 FDA-approved or near-approved cell and gene therapies. After adjusting for the cost of programs that fail along the way and applying a 10.5% cost of capital, the study estimated the risk-adjusted clinical-stage investment required to bring a cell or gene therapy to market at $1.94 billion, with a 95% confidence interval of $1.4 billion to $2.49 billion. Applying success rates specific to ex vivo cell therapy, the modality CAR-T belongs to, brought that figure down to $1.49 billion. It is worth noting this sample spans cell and gene therapy broadly, with only two of the eleven assets analyzed being CAR-T specifically, and it excludes preclinical costs entirely, which the same literature estimates could add anywhere from roughly 10% to over 40% to the total depending on methodology. The comparison is also illustrative rather than like for like: no cost data exists yet for in vivo CAR-T specifically, since none has reached approval. Even taking the more conservative end of that range, the comparison holds: an all-in, risk-adjusted cost of roughly $1.5 to $2 billion to take an asset from license to market, against up to $7 billion to acquire one that someone else has already taken there. That is not a cost saving that requires optimistic assumptions, it survives a methodology built specifically to account for failure.The odds for the CAR-T example are better than average, too. A 2023 analysis by Tufts Medical Center’s NEWDIGS program, conducted for the Alliance for Regenerative Medicine, found CAR-T and TCR-T therapies for blood cancers were three times as likely to gain approval after entering Phase 1 as the average oncology drug, against a cross-industry baseline that generally sits between 10% and 20%. Betting on this specific modality early is not simply a cheaper bet, but also a better one than the average early-stage bet across biopharma.Of course, there are caveats with this comparison and for many companies, a greater level of certainty is worth significantly greater investment. The basic economics of drug development still stand where most early bets fail. The $1.5 to $2 billion figure accounts for that and shifts the comparison being made: not one expensive asset against one cheap one, but a portfolio of small, better-than-average bets against a single near-certainty purchased at a large premium.Where the hedge comes fromActing on this calls for three specific commitments, not just observations about how this modality happens to behave. Inpart’s upcoming External R&D Playbook has been developed with industry leaders and will outline a framework of excellence and a workflow for successful S&E and external innovation. The following commitments will be discussed in more detail in the playbook. The first is triage capacity: If most of an early-stage pipeline is going unevaluated in any given window, as it is here, the direct answer is processing more of it without proportionally more headcount, whether through proactive landscaping platforms, or AI-assisted screening. Without this, a growing pipeline sees more opportunities slip through the net.The second is visibility within the originating ecosystem: Triage capacity only helps if the assets worth triaging are actually reaching a company’s desk. An institution’s decision to bring a new opportunity to one company over another is a function of whether that company has a reputation and presence in the relevant network, not just whether its BD team is fast. Inpart’s Partnering 2030 survey sheds light on the perceived ‘partner of choice’ amongst out-licensors and what qualities are sought in a successful partnership.The third is the relationship itself: Being aware of an opportunity early, and having the standing to act on it quickly and on reasonable terms, are not the same thing. Trust built with an originating institution before a specific asset exists is what converts early visibility into an actual first-mover position rather than simply an early data point.In this example, the early-stage CAR-T pipeline visible today keeps growing, and most of it still goes unengaged in any given window even as attention on the rest intensifies. This is not evidence that anyone is behind, but perhaps a preview of where the next set of billion-dollar acquisitions is being sourced from, months or years before that price tag exists.Joseph Ferner joined Inpart (the parent company of Labiotech) in 2019 after completing his PhD in synthetic organic chemistry. He has been working at the interface of scientific partnering since, running campaigns and creating reports informed by proprietary data and collaborations with external experts. This article is reserved for subscribers Subscribe for free to continue reading.Enter your details to log in or subscribe. Email Company name Job title Continue Readingor Continue with Microsoft Continue with LinkedIn By continuing, I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy. How Chiesi partners with early-stage science, and how to get on their radar Chiesi's Open Innovation leads walk through their partnering process live, featuring a live Q&A Save your seat Explore other topics: CAR-TPartnerships ADVERTISEMENT